Phase I Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris
Status:
Completed
Trial end date:
1997-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this clinical research study is to determine the safety, pharmacokinetics,
immunogenicity in humans, the recovery time required from the biologic effects and the
optimal biologic dose range of BMS188667 (CTLA4Ig)